SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up +0.72%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.18%. June E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.97%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.86%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.45%. June E-mini S&P futures (ESM26...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.52%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.68%. June E-mini S&P futures (ESM26...
Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026 ...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...